Researchers had been testing whether Artiva's off-the-shelf NK cell therapy called AB-101 could treat rheumatoid arthritis and other autoimmune diseases.
Q3 Biopharma Sentiment Index shows regulatory optimism rising after Marty Makary and Vinay Prasad's FDA exits, though scientists remain pessimistic.
Microsoft’s MAI-DxO diagnosed 83% of complex journal cases vs. 36% for doctors; a Beth Israel triage study starts within ...
Eli Lilly's Jacob Van Naarden leads aggressive dealmaking to offset tirzepatide's patent cliff, with 12+ acquisitions that ...
Roche will seek European approval for its promising new breast cancer pill giredestrant later than it once expected, ...
WuXi AppTec raises 2026 guidance again as Q3 revenue jumps 38% to $2.5B, despite its fight over the Pentagon’s Chinese military designation ...
Aspen, Bambusa eye $135M IPOs; ESMO data on AZ/Takeda ADCs, Hutchmed's Orpathys+Tagrisso, J&J's JNJ-6143, Jazz's Ziihera; ...
BioNTech and DualityBio weigh next steps after HER2 ADC trastuzumab pamirtecan posts a modest Phase 3 win in HER2-low breast ...
Akeso’s ivonescimab posts 14.9-month median OS vs. 12.1 for Imfinzi in China Ph3 biliary tract cancer trial at ESMO.
MADRID — AstraZeneca said Sunday it might have found a way for patients with mutant non-small cell lung cancer to keep ...
Pfizer’s failed Seagen ADC sigvotatug vedotin showed a 2.5-month OS edge in second-line NSCLC in a post-hoc ESMO analysis.
Basel-based Windward Bio filed for Nasdaq IPO as $WWB, advancing WIN378 and WIN027 from Kelun-Biotech, Harbour BioMed, and Qyuns for asthma, COPD, and eczema.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results